| Date | Title | Description |
| 07.05.2025 | Cognition Therapeutics Reports Financial Results for the First Quarter 2025 and Provides Business Update | - End-of-Phase 2 meeting with FDA requested for Alzheimer’s disease -
- Phase 2 results in dementia with Lewy bodies accepted for oral presentation at AAIC -
- Two posters at ARVO describe zervimesine's role supporting retinal cell health -... |
| 01.04.2025 | Cognition Therapeutics Presents Results at AD/PD 2025 Showing Impact of Zervimesine (CT1812) on Alzheimer’s Disease Processes | PURCHASE, N.Y., April 01, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, presented biomarker results fr... |
| 20.03.2025 | Cognition Therapeutics Reports Year End 2024 Financial Results and Provides Business Update | Positive Results with Zervimesine (CT1812) in Phase 2 SHIMMER Dementia with Lewy Bodies (DLB)
Phase 2 SHINE Data Show Dramatic Slowing of Cognitive Decline with Zervimesine in a Key Pre-specified Alzheimer’s Disease Subgroup
2025 Objective:... |
| 14.03.2025 | Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing | Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
NEW YORK, March 14, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the p... |
| 13.03.2025 | Cognition Therapeutics to Report Fourth Quarter and Full Year 2024 Results | PURCHASE, N.Y., March 13, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing product candidates that treat neurodegenerative disorders, (the “Company” or “Cognition”), plans to release ... |
| 13.03.2025 | Cognition Therapeutics to Report Fourth Quarter and Full Year 2024 Results | Conference Call and Live Audio Webcast Scheduled for March 20, 2025
PURCHASE, N.Y., March 13, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing product candidates that treat neurodegen... |
| 12.03.2025 | Cognition Therapeutics Granted Extension to Meet Nasdaq Minimum Bid Price Requirement for Continued Exchange Listing | PURCHASE N.Y., March 12, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing product candidates that treat neurodegenerative disorders, (the “Company” or “Cognition”), was notified by th... |
| 27.02.2025 | Cognition Therapeutics Publishes Research Supporting the Potential of Zervimesine in Dry AMD | PURCHASE, N.Y., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing neurodegenerative disease candidates, (the “Company” or “Cognition”) announced the publication of a manuscrip... |
| 30.01.2025 | Cognition’s Positive Phase 2 ‘SHIMMER’ Study of Zervimesine (CT1812) in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at ILBDC | – Study demonstrated strong therapeutic responses across behavioral, functional, cognitive, and movement measures in patients with mild-to-moderate DLB –
– Zervimesine-treated participants tested 86% better on behavioral outcomes (NPI A-L),... |
| 30.01.2025 | Cognition’s Positive Phase 2 ‘SHIMMER’ Study of Zervimesine (CT1812) in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at ILBDC | – Study demonstrated strong therapeutic responses across behavioral, functional, cognitive, and movement measures in patients with mild-to-moderate DLB –
– Zervimesine-treated participants tested 86% better on behavioral outcomes (NPI A-L),... |
| 08.01.2025 | Cognition Therapeutics CEO Participating in Longwood and Sachs Conferences | PURCHASE, N.Y., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that CEO Lisa Ricciar... |
| 18.12.2024 | Cognition Therapeutics Announces Positive Results in Phase 2 Study of CT1812 in Dementia with Lewy Bodies | - Improvements Across Measures of Behavior, Function, Cognition and Movement -
- Expediting Plans to Advance CT1812 into Late-Stage Trials -
- Full Results to be Presented at International Lewy Body Dementia Conference (ILBDC) -
- Cognition... |
| 13.11.2024 | Cognition Therapeutics Reports Financial Results for the Third Quarter 2024 and Provides Business and Clinical Update | - CT1812 slowed cognitive decline by 95% in Alzheimer’s disease patients with lower levels of plasma p-tau217 in a pre-specified analysis from Phase 2 SHINE study presented at CTAD -
- On track to report topline results from Phase 2 SHIMMER... |
| 12.11.2024 | Cognition Therapeutics to Present at Zacks SCR Life Sciences Investor Forum | PURCHASE, N.Y., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that President and CE... |
| 31.10.2024 | Cognition Therapeutics Presents Poster of Participant Demographics from Phase 2 Dementia with Lewy Bodies Study at CTAD | - Patient characteristics are consistent with other DLB studies -
PURCHASE, N.Y., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that ... |
| 29.10.2024 | Cognition Therapeutics Announces Results of Pre-specified Analysis of SHINE Study Data Presented at CTAD | - Results show CT1812 dramatically slowed cognitive decline in patients with lower levels of plasma p-tau217, an important biomarker of Alzheimer’s disease pathology -
- ADAS-Cog 11 scores showed 95% slowing of decline -
- MMSE scores showe... |
| 22.10.2024 | Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Executing Clinical Research in Dementia with Lewy Bodies (DLB) | PURCHASE, N.Y., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, has released a new Conversations... |
| 02.10.2024 | ROTH to Host 3rd Annual Healthcare Opportunities Conference on October 9 in New York City | Conference to Feature Leading Healthcare Companies and Institutional Investors for 1x1/Small Group Meetings and Panels
NEW YORK, Oct. 02, 2024 (GLOBE NEWSWIRE) -- via IBN -- ROTH Capital Partners, LLC (“ROTH”), www.roth.com, is pleased to a... |
| 02.10.2024 | Cognition Therapeutics Will Participate in the Roth Healthcare Opportunities Conference | PURCHASE, N.Y., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs to treat neurodegenerative disorders, today announced the Company’s pres... |
| 02.10.2024 | Cognition Therapeutics Will Participate in the Roth Healthcare Opportunities Conference | PURCHASE, N.Y., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs to treat neurodegenerative disorders, today announced the Company’s pres... |
| 03.09.2024 | Cognition Therapeutics to Participate in Upcoming September 2024 Investor Conferences | PURCHASE, N.Y., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, today announced the Company’s p... |
| 08.08.2024 | Cognition Therapeutics Reports Financial Results for the Second Quarter 2024 and Provides Business and Clinical Update | - Proof-of-Concept Phase 2 SHINE Trial Demonstrates ~40% Mean Improvement in ADAS-Cog 11 vs Placebo and Consistent Positive Changes Across Multiple Cognitive and Functional Measures -
- On Track to Report Topline Results from SHIMMER Study ... |
| 05.08.2024 | Cognition Therapeutics to Report Second Quarter 2024 Financial Results | - Conference Call and Live Audio Webcast Scheduled for August 8, 2024 -
PURCHASE, NY.., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing product candidates that treat neurode... |
| 05.08.2024 | Cognition Therapeutics to Report Second Quarter 2024 Financial Results | PURCHASE, NY.., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing product candidates that treat neurodegenerative disorders (the “Company” or “Cognition”), today announced tha... |
| 29.07.2024 | Cognition Therapeutics’ Proof-of-Concept Phase 2 SHINE Trial Demonstrates Consistent Improvement in Cognitive Outcomes with Once-Daily Oral CT1812 in Mild-to-Moderate Alzheimer’s Patients | - CT1812 Treatment Showed ~40% Mean Improvement in Cognitive Measures vs Placebo -
- Consistent Positive Changes Across Cognitive and Functional Measures -
- Favorable Safety Profile with Most Treatment-Related Adverse Events Mild or Modera... |
| 26.07.2024 | Cognition Therapeutics to Host Investor Webcast to Discuss Results from Proof-of-Concept Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease at 8:30am ET on Monday July 29, 2024 | PURCHASE, N.Y., July 26, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders will host an investor webcast on ... |
| 02.07.2024 | Results from Cognition Therapeutics’ Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease Accepted for Presentation at AAIC | PURCHASE, N.Y., July 02, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, today announced that abstracts s... |
| 02.07.2024 | Results from Cognition Therapeutics’ Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease Accepted for Presentation at AAIC | PURCHASE, N.Y., July 02, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, today announced that abstracts s... |
| 07.05.2024 | Cognition Therapeutics Reports Financial Results for the First Quarter 2024 and Provides Business Update | - Topline Results from SHINE Study in Mild-to-Moderate Alzheimer’s Expected Mid-2024 -
- SHIMMER Study in Dementia with Lewy Bodies Completed Enrollment of 130 Participants -
PURCHASE, N.Y., May 07, 2024 (GLOBE NEWSWIRE) -- Cognition Therap... |
| 14.03.2024 | Cognition Therapeutics Announces Closing of $11.5 Million Public Offering of Common Stock | - |
| 13.03.2024 | Cognition Therapeutics Announces Public Offering | Cognition Therapeutics, a company focused on treating neurodegenerative disorders, has priced a public offering of common stock at $1.75 per share. The offering is expected to raise approximately $11.5 million, with the option for additiona... |
| 12.03.2024 | Cognition Therapeutics Announces Pricing of $11.5 Million Public Offering of Common Stock | PURCHASE, N.Y., March 11, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (“Cognition,” the “Company” or “We”) (Nasdaq: CGTX), a clinical stage company developing product candidates designed to treat neurodegenerative disorders, today... |
| 11.03.2024 | Cognition Therapeutics Announces Pricing of $11.5 Million Public Offering of Common Stock | - |
| 11.03.2024 | Cognition Therapeutics Announces Proposed Public Offering of Common Stock | PURCHASE, N. Y., March 11, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (“Cognition,” the “Company” or “We”) (Nasdaq: CGTX), a clinical stage company developing product candidates designed to treat neurodegenerative disorders, toda... |
| 11.03.2024 | Cognition Therapeutics Announces Proposed Public Offering of Common Stock | - |
| 06.03.2024 | Cognition Therapeutics Presents Analyses at AD/PD™ 2024 Correlating Proteomic Findings with Treatment Effect of CT1812 in Alzheimer’s Disease Studies | - |
| 27.10.2023 | Cognition Therapeutics and Collaborators at Yale and ACTC Announce Oral Late-breaking Presentation on the START Study in Early Alzheimer’s Disease at CTAD | NEW YORK, Oct. 27, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX) announced that Christoper van Dyck, M.D., the director of the Yale Alzheimer's Disease Research Unit and the Yale Alzheimer's Disease Research Center, i... |
| 04.05.2023 | Cognition Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update | /EIN News/ -- Completed enrollment for Phase 2 SEQUEL trial in mild-to-moderate Alzheimer’s disease (AD); topline results expected 2Q 2023
SHINE (AD) trial currently enrolling patients with first patient in Spain enrolled. Expect full enrol... |
| 09.08.2022 | Cognition Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update | Cognition Therapeutics reported on 2nd quarter financial results and business updates including optimistic advancements in clinical trials. |
| 04.08.2022 | Cognition Therapeutics Presents New Proteomic Data on Effect of CT1812 Treatment on Normalization of Disrupted Alzheimer’s Disease Processes | Analytic results in a study of Cognition Therapeutic’s CT1812, a drug targeting mild-to-moderate Alzheimer’s disease, indicates a reduction in the YKL-40, a biomarker for inflammation associated with Alzheimer’s. |
| 30.03.2022 | Cognition Therapeutics Reports Year End 2021 Financial Results | Read full Press Release here. |
| 18.11.2021 | Cognition Therapeutics Reports Third Quarter Financial Results and Company Highlights | PURCHASE, N.Y., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-rela... |
| 13.10.2021 | Sofia portfolio company Cognition Therapeutics goes public | Women-led biopharmaceutical company Cognition Therapeutics newly public stock started trading Oct. 8. CGTX (new NASDAQ ticker) innovates therapeutics that target age-related degenerative diseases and disorders. See the news here: https://ir... |
| 12.10.2021 | IPO roundup: These 3 tech exits will yield big gains for Pittsburgh | After Duolingo’s hugely successful initial public offering in July, Pittsburgh tech leaders shared predictions of a chain of similar exits to follow soon after. And they were right.
Only a few short months later, another Pittsburgh tech com... |
| 04.10.2021 | Cognition Therapeutics launched its $40M IPO for Alzheimer’s treatment | Yet another Pittsburgh company is set to go public. But this time, it’s a small life sciences firm.
On Monday, drug discovery company Cognition Therapeutics launched its initial public offering, which it announced and filed for at the end o... |
| 20.10.2020 | Cognition Therapeutics Elucidates Genetic Mutation that Protects Against Alzheimer’s Disease | Mutation Validates Cognition Approach to Oligomer Displacement |
| 31.08.2020 | Cognition Therapeutics Announces First Patient Dosed in SEQUEL Study | Pittsburgh, August 27, 2020 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc., a clinical stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular damage response pathways announced that it has... |
| 09.06.2020 | Cognition Therapeutics Receives $75.8 Million NIA Grant | Sofia portfolio company Cognition Therapeutics awarded $75.8M in competitive grant process, to study efficacy of its technology with early Alzheimer’s patients |
| 08.06.2020 | Cognition Therapeutics Receives $75.8 Million NIA Grant | - |
| 20.11.2019 | Cognition Therapeutics to Give Webcast Presentation at Annual Piper Jaffray Healthcare Conference on December 3, 2019 | Pittsburgh, PA, November 20, 2019 (GLOBE NEWSWIRE) – Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in Alzheimer’s disease and other neurodegenerative disor... |
| 01.08.2019 | CogRX Gains Patent Coverage in Japan and China | Portfolio company CogRX gains patent coverage in Japan and China for Elayta, Cognition’s lead drug for treatment of mild to moderate Alzheimer’s disease. |
| 16.07.2019 | Cognition Therapeutics Receives $3.3 Million NIA Grant to Conduct qEEG Study of Elayta™ with World-Leading Alzheimer’s Biomarker Experts | Investigating Quantitative EEG as Biomarker of Patient Response to Treatment in Future Efficacy Studies |
| 06.06.2019 | Cognition Therapeutics Appoints Anthony O. Caggiano M.D., Ph.D. to the Position of Chief Medical Officer | Pittsburgh, PA, June 05, 2019 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc., today announced that Anthony O. Caggiano, M.D., Ph.D. has joined the Company as chief medical officer (CMO). Cognition Therapeutics is a clinical stage neuroscie... |
| 26.03.2019 | Cognition Therapeutics Elects Lisa Ricciardi to its Board of Directors | Pittsburgh, PA, March 26, 2019 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in neurodegenerative diseases and disorders caused by membr... |
| 21.02.2019 | Cognition Therapeutics Receives European Patent Covering its Alzheimer’s Disease Candidate, Elayta™ | Pittsburgh, PA, February 21, 2019 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in neurodegenerative diseases and disorders, today annou... |
| 19.02.2019 | Cognition Therapeutics Announces Publication of Complete Results from Phase 1 Clinical Trial of Elayta™ | Elayta Crossed Blood Brain Barrier and Reached CNS Levels Associated in Preclinical Studies with Cognitive Improvement |
| 04.10.2018 | CogRX receives $16.6M Grant for Phase II Study of Alzheimer’s Drug | Sofia Fund portfolio company CogRX has received a $16.6M Multi-Year Grant for Phase II studies of its Elayta™ drug for mild-to-moderate Alzheimer’s disease. Learn more at CogRX announces NIA grant |
| 27.03.2018 | Sofia Fund Makes Third Investment in Cognition Therapeutics | Sofia Fund recently announced its third investment in Cognition Therapeutics, Inc. (CogRx), a Pittsburgh-based biopharmaceutical company that discovers, develops and manufactures innovative therapeutics for the treatment of Alzheimer’s dise... |
| 13.01.2016 | Five of Biotech Showcase’s most interesting startups | Interestingly, none of these startups are located in the usual geographical suspects: Boston, San Francisco and San Diego.
Aegle Therapeutics Corp.
This regenerative medicine startup is developing microvesicles – that is, fragments of plasm... |
| 09.09.2015 | Daily funding roundup - September 9, 2015 | Didi Kuaidi scored $1B; Chef bagged $40M; Primus Power raised $25M
The battle for supremacy among e-hailing services in China is heating up, and fast. In the same week that Uber revealed that it has raised an additional $1.2 billion to expa... |
| 08.09.2015 | Cognition Therapeutics Completes $12M Series B Financing | Cognition Therapeutics Inc., a Pittsburgh, PA-based pharmaceutical company focused on discovering and developing disease-modifying therapies for Alzheimer’s and related neurodegenerative diseases, completed a $12m Series B financing.
The ro... |
| 08.09.2015 | Cognition Therapeutics Completes Oversubscribed $12 Million Series B Financing | - |
| 11.10.2013 | Cognition Therapeutics Raises $138K in Funding | Cognition Therapeutics, Inc., a Pittsburgh, PA-based drug discovery company focused on neurodegenerative disorders, raised $138k in funding.
Pittsburgh Life Sciences Greenhouse (PLSG), managing member of the PLSG Accelerator Fund, made this... |
| 23.05.2013 | After a restructure and an axed Merck deal, Acumen gains $20M for novel Alzheimer’s drug | They found that soluble oligomers they called amyloid beta-derived diffusible ligands, or ADDLs, were toxic to neurons and proposed that ADDLs were important to the cause of Alzheimer’s disease. That was controversial at the time, Goure sai... |
| 30.04.2013 | Women to watch: MedCity News’s nominees for 40 women over 40 | “…where our wealth of knowledge and know-how can move innovation into overdrive. It is a time where we are supremely motivated to do not just for ourselves, but for others, as we ask the question, What can I do to make my life really count?... |
| 08.01.2013 | Biotech CEO advancing Alzheimer’s disease treatment sees thaw in “nuclear winter” of funding | “We are probably one of the only biotechs in existence that has discovered a very significant and potent way to block the activity of these toxic proteins,” said CEO Hank Safferstein, in a phone interview.
“The whole industry has become lik... |
| 12.12.2011 | Alzheimer’s drug developer Cognition Therapeutics raises $1.8M | The latest funding was sourced from 16 investors, according to the regulatory document.
Cognition’s technology is aimed at blocking Amyloid beta protein, which can interfere with learning and memory. Blocking the effects of the protein may ... |
| 25.10.2011 | At Biotech 2011, companies identify financing options | Government funding. If you want government funding, get to know your local congressmen, one panelist advised. Government grants can be a useful source of funding, particularly the Department of Defense. It might take time and the applicatio... |
| 20.01.2011 | Cognition Therapeutics Closes $2.5M Series A1 Financing | Cognition Therapeutics, Inc., a Pittsburgh, PA-based drug discovery company developing novel, small molecule disease-modifying treatments for Alzheimer’s, has closed on a $2.5m Series A1 financing.
The round was led by Golden Seeds, with pa... |
| 20.01.2011 | Alzheimer’s drugmaker Cognition Therapeutics raises $2.5M | “This financing increases our investor base and further expands our national network to support the critical work we are doing to identify drugs that can treat and potentially prevent the progression of Alzheimer’s disease,” CEO Hank Saffer... |
| 16.07.2009 | Alzheimer’s-blocking drug developer Cognition Therapeutics raises $1.2 million | Cognition moved to Pittsburgh about two years ago from California. The advancements developed by the company are licensed from California State University Channel Islands.
Promoted
Clinical Care Capacity Planning
Learn how to manage clinica... |
| 17.06.2009 | Louisiana pharma startup TheraVasc moves, readies for clinical trials | “In 18 months, I hope to have completed clinical data and [to be] moving on to Phase II tests,” Giordano said.
TheraVasc uses existing drugs and applies them in different forms or combines them to treat new diseases. Its drug to treat peri... |
| - | Alzheimer’s drugmaker Cognition Therapeutics raises $2.5M | Neurodegenerative disorders drug developer Cognition Therapeutics has raised $2.5 million in a Series A1 round of investment.
The funding will support preclinical research as the Pittsburgh-based company investigates which of its drug candi... |
| - | Alzheimer’s drug developer Cognition Therapeutics raises $1.8M | Neurodegenerative disorders drug developer Cognition Therapeutics has raised $1.8 million in equity, according to a regulatory filing.
The Pittsburgh-based company is developing multiple drug candidates to treat Alzheimer’s disease and simi... |
| - | Women to watch: MedCity News’s nominees for 40 women over 40 | One of the first things I learned in my conversations with industry insiders after joining MedCity News was this: while you might find a lot of young people starting health IT companies, most life science entrepreneurs tend to be an older s... |
| - | Alzheimer’s-blocking drug developer Cognition Therapeutics raises $1.2 million | PITTSBURGH, Pennsylvania — Cognition Therapeutics has raised $1.2 million to further study of its tests and treatments of specific proteins that could detect and stop Alzheimer’s disease.
Cognition focuses on detecting the Abeta proteins fo... |
| - | At Biotech 2011, companies identify financing options | The challenge of identifying and establishing financing for early and mid-stage companies is forcing companies to be more creative and making the series of panel discussions on the subject at Biotech 2011 in Philadelphia a high priority as ... |
| - | Five of Biotech Showcase’s most interesting startups | Presenting at the J.P. Morgan Healthcare Conference may confer some level of credibility to a company – but several worthy startups are showcased each year at the neighboring Biotech Showcase.
Some 300 biotechnology companies – public and p... |
| - | Louisiana pharma startup TheraVasc moves, readies for clinical trials | CLEVELAND, Ohio — A pharmaceutical start-up focused on cardiovascular disease plans to move to Cleveland and start clinical trials on at least one drug this fall.
TheraVasc, based in Shreveport, La., wants to raise $2.5 million in its firs... |
| - | Biotech CEO advancing Alzheimer’s disease treatment sees thaw in “nuclear winter” of funding | Several companies have suffered setbacks with drugs to treat Alzheimer’s disease, but one biotechnology entrepreneur believes his company’s approach offers hope to those with loved ones who have the neurodegenerative disease.
The ability to... |
| - | After a restructure and an axed Merck deal, Acumen gains $20M for novel Alzheimer’s drug | It’s been 17 years in the making, but Acumen Pharmaceuticals hasn’t given up hope for its approach to a disease-modifying drug for Alzheimer’s disease. After restructuring to become a virtual biotech and raising a $20 million Series A, Acum... |
